Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + lenvatinib + cisplatin + carboplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This is a neoadjuvant combination therapy regimen being evaluated for the treatment of surgically resectable esophageal squamous cell carcinoma (ESCC). The regimen consists of **QL1706**, a novel bifunctional biologic developed by Qilu Pharmaceutical that combines **iparomlimab** (an anti-PD-1 IgG4 monoclonal antibody) and **tuvonralimab** (an anti-CTLA-4 IgG1 monoclonal antibody) in a fixed 2:1 ratio. This is combined with **lenvatinib**, a multi-kinase inhibitor targeting VEGFR 1-3, FGFR 1-4, PDGFR-α, KIT, and RET, and a chemotherapy backbone comprising a platinum agent (**cisplatin** or **carboplatin**) and **nab-paclitaxel** (albumin-bound paclitaxel). The combination aims to leverage the synergistic anti-tumor effects of dual immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy in the locally advanced resectable setting.
- Other names
- QL1706 + lenvatinib + chemotherapyiparomlimab and tuvonralimab + lenvatinib + cisplatin/carboplatin + nab-paclitaxel
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAFGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + lenvatinib + cisplatin + carboplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + lenvatinib + cisplatin + carboplatin + nab-paclitaxel.